1. CHARACTERISTICS AND SURVIVAL RESULTS OF PERITONEAL DIALYSIS PATIENTS SUFFERING FROM COVID-19 IN TURKEY: A MULTICENTER NATIONAL STUDY
- Author
-
Meltem Gursu, Savas Ozturk, Mustafa Arici, Idris Sahin, Sibel Gökçay Bek, Murvet Yilmaz, Sumeyra Koyuncu, Semahat Karahisar Şirali, Zeynep Ural, Belda Dursun, Enver Yuksel, Sami Uzun, Savaş Sipahi, Elbis Ahbap, Ayse Serra Artan, Orcun Altunoren, Onur Tunca, Yavuz Ayar, Ebru Gok-Oguz, Zulfukar Yilmaz, Serdar Kahvecioglu, Ebru Asicioglu, Aysegul Oruc, Mehmet Riza Altiparmak, Zeki Aydin, Bulent Huddam, Murside Esra Dolarslan, Alper Azak, Serkan Bakirdogen, Ahmet Ugur Yalcin, Serhat Karadag, Memnune Sena Ulu, Ozkan Gungor, Elif Ari Bakir, Ali Riza Odabas, Nurhan Seyahi, Alaattin Yildiz, and Kenan Ates
- Subjects
Dermatology ,RL1-803 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Background: We aimed to study the characteristics of peritoneal dialysis (PD) patients with Coronavirus disease-19 (COVID-19), determine the short-term mortality and other medical complications, and delineate the factors associated with COVID-19 outcome. Methods: In this multicenter national study, we included PD patients with confirmed COVID-19 from 27 centers. The baseline demographic, clinical, laboratory, and radiological data and outcomes at the end of the first month were recorded. Results: We enrolled 142 COVID-19 patients (median age:52 years). 58.2% of patients had mild disease at diagnosis. Lung involvement was detected in 60.8% of patients. 83 (58.4%) patients were hospitalized, 31 (21.8%) patients were admitted to intensive care unit and 24 needed mechanical ventilation. 15 (10.5%) patients were switched to hemodialysis and hemodiafiltration was performed for four (2.8%) patients. Persisting pulmonary symptoms (n=27), lower respiratory system infection (n=12), rehospitalization for any reason (n=24), malnutrition (n=6), hypervolemia (n=13), peritonitis (n=7), ultrafiltration failure (n=7) and in PD modality change (n=8) were reported in survivors. 26 patients (18.31%) died in the first month of diagnosis. The non-survivor group was older, comorbidities were more prevalent. Fever, dyspnea, cough, serious-vital disease at presentation, bilateral pulmonary involvement, and pleural effusion were more frequent among non-survivors. Age (OR:1.102; 95%CI: 1.032-1.117; p: 0.004), moderate-severe clinical disease at presentation (OR:26.825; 95%CI: 4.578-157.172; p
- Published
- 2022
- Full Text
- View/download PDF